ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Adverse events"

  • Abstract Number: 173 • 2013 ACR/ARHP Annual Meeting

    HLA-DRB1*08:02 Is Associated With Bucillamine-Induced Proteinuria In Japanese Rheumatoid Arthritis Patients: A Case-Control Study

    Hiroshi Furukawa1, Shomi Oka1, Kota Shimada2, Shoji Sugii2, Atsushi Hashimoto3, Akiko Komiya1, Naoshi Fukui1, Taiichiro Miyashita4, Kiyoshi Migita4, Akiko Suda5, Shouhei Nagaoka6, Naoyuki Tsuchiya7 and Shigeto Tohma1, 1Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 2Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 3Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 4Clinical Research Center, Nagasaki Medical Center, National Hospital Organization, Omura, Japan, 5Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, 6Department of Rheumatology, Yokohama Minami Kyousai Hospital, Yokohama, Japan, 7Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

    Background/Purpose: Bucillamine (Buc) is one of the commonly used disease-modifying anti-rheumatic drugs (DMARDs) in Japan. Drug-induced proteinuria can occur in rheumatoid arthritis (RA) patients treated…
  • Abstract Number: 442 • 2013 ACR/ARHP Annual Meeting

    Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy

    A. Dikranian1, K. Soma2, R. Riese2, D. Gruben2 and T. V. Jones3, 1San Diego Arthritis Medical Clinic, San Diego, CA, 2Pfizer Inc, Groton, CT, 3Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tolerability remains an ill-defined construct in clinical trials.…
  • Abstract Number: 2626 • 2013 ACR/ARHP Annual Meeting

    Infliximab For Sight-Threatening and Refractory Uveitis Of Behcet’s Syndrome

    Vedat Hamuryudan1, Gulen Hatemi2, Yilmaz Ozyazgan2, Didar Ucar2, Sebahattin Yurdakul2, Emire Seyahi2, Koray Tascilar2, Serdal Ugurlu2 and Hasan Yazici3, 1Division of Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, 2Cerrahpasa Medical Faculty University of Istanbul, Behcet's Syndrome Research Center, Cerrahpasa Medical Faculty University of Istanbul, Istanbul, Turkey, 3Cerrahpasa Medical Faculty University of Istanbul, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey

    Background/Purpose: Uncontrolled studies suggest a beneficial effect of infliximab in the treatment of severe uveitis of BS. The majority of these studies had short observation…
  • Abstract Number: 459 • 2013 ACR/ARHP Annual Meeting

    Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis

    MC Genovese1, Joel M. Kremer2, Ronald F. van Vollenhoven3, Rieke Alten4, Juan José Scali5, Ariella Kelman6, Lucy Rowell7 and Laura Pitts7, 1Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, 2Center for Rheumatology, Albany Medical College, Albany, NY, 3Karolinska Institute, Stockholm, Sweden, 4Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, 5Durand University Hospital, Buenos Aires, Argentina, 6Genentech, South San Francisco, CA, 7Roche, Welwyn Garden City, United Kingdom

    Background/Purpose: The interleukin-6 receptor inhibitor tocilizumab (TCZ) has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving function and is well tolerated in patients…
  • Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting

    Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis

    Mitsuhiro Takeno1, Kayo Terauchi1, Yohei Kirino1,2, Ryusuke Yoshimi1, Nobuhisa Mizuki2, Etsuko Shibuya3 and Yoshiaki Ishigatsubo2, 1Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Yokohama City University Graduate School of Medicine, Yokohama, Japan, 3Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…
  • Abstract Number: 2351 • 2013 ACR/ARHP Annual Meeting

    Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials

    Ronald F. van Vollenhoven1, Andrea Rubbert-Roth2, Anthony Sebba3, Benjamin Porter-Brown4, Lucy Rowell5, Pavel Napalkov6 and Devi Smart5, 1Karolinska Institute, Stockholm, Sweden, 2Med Clinic I, University of Cologne, koln, Germany, 3University of South Florida, Tampa, FL, 4Roche Products Ltd., Welwyn Garden City, United Kingdom, 5Roche, Welwyn Garden City, United Kingdom, 6Epidemiology, Genentech, South San Francisco, CA

    Background/Purpose: Malignancy is a potential risk of immunomodulatory treatments and may be increased in patients (pts) with rheumatoid arthritis (RA). The risk of malignancy was…
  • Abstract Number: 2362 • 2013 ACR/ARHP Annual Meeting

    Incidence Of Adverse Events In Patients With Rheumatoid Arthritis and Spondyloarthritis Exposed To Anti-TNF Therapy. Data From The Brazilian Registry For Monitoring Of Biologic Therapies In Rheumatic Diseases (BiobadaBrasil)

    Roberto Ranza1, David C Titton2, Valeria Vallim3, Ines Silveira4, Aline Ranzolin5, Andre Hayata6, Mirhelen M. Abreu7, Paulo Louzada-Jr8, Angela LBP Duarte5, Claiton Brenol9, Geraldo C Pinheiro10, Glaucio R Castro11, Hellen M Carvalho12, Isaias Costa13, Jose C Macieira14, Jose R Miranda15, Julio CM Bertacini16, Luis SG Barbosa17, Manoel B Bertolo18, Marcelo M. Pinheiro12, Maria F Sauma19, Marilia B Silva20, Marlene Freire21, Roberto A Toledo22 and Vander Fernandes23, 1Universidade Federal de Uberlandia, Uberlandia MG, Brazil, 2Hospital de Clínicas da UFPR, Curitiba PR, Brazil, 3Universidade Federal do Espirito Santo, Vitoria ES, Brazil, 4PUCRS, Porto Alegre RS, Brazil, 5Universidade Federal de Pernambuco, Recife PE, Brazil, 6CRO Osasco, Osasco SP, Brazil, 7Universidade Federal de São Carlos, São Carlos SP, Brazil, 8USP RP, Ribeirão Preto SP, Brazil, 9Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, 10UERJ, Rio de Janeiro RJ, Brazil, 11Hospital Governador Celso Ramos, Florianopolis SC, Brazil, 12Brazilian Registry of Spondyloarthritis, São Paulo, Brazil, 13Universidade Federal MS, Campo Grande MS, Brazil, 14UFS Aracaju, Aracaju SE, Brazil, 15Artrocenter Clinica Medica, Taubate SP, Brazil, 16USP SP CDMAC, São Paulo SP, Brazil, 17Universidade Federal Mato Grosso, Cuiabá MT, Brazil, 18UNICAMP, Campinas SP, Brazil, 19UFPA, Belem PA, Brazil, 20Hospital Universitario Evangelico, Curitiba PR, Brazil, 21UFTM, Uberaba MG, Brazil, 22FUNFARP, São José do Rio Preto SP, Brazil, 23Universidade de Cuiabá, Cuiaba MT, Brazil

    Background/Purpose: The safety profile of a-TNF biologic drugs might have substantial regional differences due to geographic and socio economic factors and to epidemiology of infectious…
  • Abstract Number: 2048 • 2013 ACR/ARHP Annual Meeting

    Risk Factors For Glucocorticoids-Induced Diabetes In Patients With Rheumatic Diseases

    Takayuki Katsuyama1, Sayaka Aoki2, Ken-ei Sada3, Yuriko Yamamura1, Haruki Watanabe1, Eri Katsuyama1, Mariko Narazaki1, Noriko Tatebe1, Koichi Sugiyama1, Katsue S. Watanabe3, Hiroshi Wakabayashi1, Tomoko Kawabata1, Jun Wada4 and Hirofumi Makino3, 1Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, 2Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 3Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, 4Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

    Background/Purpose: Since the efficacy of glucocorticoids for various rheumatic diseases was reported, glucocorticoids are still one of the important therapeutic agents in the current treatment…
  • Abstract Number: 1865 • 2013 ACR/ARHP Annual Meeting

    Complement Activation and Anaphylatoxin Generation In Response To Staphylococcal Protein A Exposure: Ex Vivo and In Vivo Human Studies

    Edward Bernton1, Antonio Polley2, Susan Zondlo2, Lynne Mitchell3 and Dennis Hourcade3, 1Protalex Inc., Summit, NJ, 2QPS Holdings LLC, Newark, DE, 3Division of Rheumatology, Washington University School of Medicine, St. Louis, MO

    Background/Purpose: PRTX-100, a highly-purified GMP staphylococcal protein A (SpA), is currently in clinical trials treating patients with active rheumatoid arthritis (RA). It has been reported…
  • Abstract Number: 2158 • 2012 ACR/ARHP Annual Meeting

    Baseline Folate Related Biomarkers in Serum and erythrocytes Are Not Associated with Methotrexate Response and Adverse Events in Rheumatoid Arthritis

    Maurits C.F.J. De Rotte1, Saskia M.F. Pluijm2, Maja Bulatovic3, Johanna M.W. Hazes4 and Robert De Jonge1, 1Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, 2Public Health, Erasmus Medical center, Rotterdam, Netherlands, 3Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, 4Rheumatology, Erasmus MC, Rotterdam, Netherlands

    Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
  • Abstract Number: 2161 • 2012 ACR/ARHP Annual Meeting

    Methotrexate Polyglutamate Concentrations in Erythrocytes Are a Potential Tool for Therapeutic Drug Monitoring of Methotrexate Response in Rheumatoid Arthritis

    Maurits C.F.J. De Rotte1, Ethan den Boer2, Maja Bulatovic3, Saskia M.F. Pluijm4, Johanna M.W. Hazes5 and Robert De Jonge1, 1Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, 2Clinical Chemistry, Erasmus University Hospital, Rotterdam, Netherlands, 3Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, 4Public Health, Erasmus Medical center, Rotterdam, Netherlands, 5Rheumatology, Erasmus MC, Rotterdam, Netherlands

    Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
  • Abstract Number: 1853 • 2012 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis Patients’ Experiences of Medication Side Effects and Subsequent Decision Making about Medications

    Yomei Shaw1, Ilinca D. Metes2, Susan L. Zickmund3, Dawn McBride2, Kelly A. Reckley2, Stephen R. Wisniewski4, Larry W. Moreland2, Mark S. Roberts1 and Marc C. Levesque2, 1Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 2Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 3Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA

    Background/Purpose:  Medication adherence in rheumatoid arthritis (RA) patients can be influenced by their previous experiences with medication side effects.  Negative experiences may lead patients to…
  • Abstract Number: 1854 • 2012 ACR/ARHP Annual Meeting

    The Safety of Anti-TNF Biologic Agents in Rheumatoid Arthritis – A Meta-Analysis of 35 RCTs

    Tzuyu Lin1, Tatyana Shamliyan1, Hyon Choi2, Young Hee Rho3 and Karen Kuntz1, 1Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, 2Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 3Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: The objectives of this systematic review were to study and update the safety of anti-TNF agents. We examined whether etanercept (ETN), compared to the…
  • Abstract Number: 1298 • 2012 ACR/ARHP Annual Meeting

    Improvement of Treatment Outcome of Rheumatoid Arthritis with Salazosulfapyridine by Pharmacogenetic Approach

    Shunichi Kumagai1, Yoshiaki Hagiwara2, Yoshihide Ichise1, Sho Sendo3, Nobuhiko Okada1, Jun Saegusa4 and Goh Tsuji5, 1Center of rheumatic diseases, Shinko hospital, Kobe, Japan, 2Department of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, 3Center of rheumatic diseases, Shinko Hospital, Kobe, Japan, 4Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 5Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan

    Background/Purpose: Salazosulfapyridine (SASP) is acetylated in liver by N-acetyltransferase2 (NAT2) in the track of metabolism. Previous studies have shown that genotyping of NAT2 is adequate…
  • Abstract Number: 1242 • 2012 ACR/ARHP Annual Meeting

    Use of Anti-Tumor Necrosis Factor Therapy Is Associated with Reduced Cardiovascular Event Risk in Rheumatoid Arthritis

    Mike Nurmohamed1, Yanjun Bao2, James Signorovitch3, Parvez M. Mulani4 and Daniel Furst5, 1VU University Medical Center & Jan van Breemen Research Institute, Amsterdam, Netherlands, 2AbbVie, North Chicago, IL, 3Analysis Group, Inc., Boston, MA, 4Abbott Laboratories, Abbott Park, IL, 5Div of Rheumatology, UCLA Medical School, Los Angeles, CA

    Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risks for cardiovascular (CV) comorbidities because of an increased prevalence of traditional CV risk factors and the…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology